8-K: Outset Medical Reports Strong Q1 Growth Driven by Console and Recurring Revenue

Outset Medical's first quarter 2025 results show a 6% revenue increase and significant progress in gross margin expansion and cash use reduction.

Summary

• Outset Medical reported its first quarter 2025 financial results, showcasing growth in key areas.
• Net revenue reached $29.8 million, a 6% increase compared to the prior-year period.
• Tablo console revenue grew by 23% from the fourth quarter.
• Recurring revenue, consisting of Tablo consumables and services, increased by 20% year-over-year to $22.7 million.
• The company shipped its 3 millionth Tablo treatment during the quarter, adding 1 million treatments in approximately 12 months.
• Gross margin improved to 37.2%, with non-GAAP gross margin reaching 37.6%, a more than 6 percentage point increase from the prior year.
• Excluding stranded manufacturing overhead costs, non-GAAP gross margin would have been approximately 40%.
• Net cash used in operating activities decreased by 44% compared to the first quarter of 2024.
• The company reiterated its 2025 revenue guidance of $115 million to $125 million and expects non-GAAP gross margin in the high-30% range.
• Outset anticipates using less than $50 million of cash in 2025, compared to $103 million in 2024.

Sentiment

Score: 7

Explanation: The report is generally positive, highlighting revenue growth, margin improvement, and reduced cash burn; however, the company is still operating at a loss, which tempers the overall sentiment.

Positives

• Strong growth in Tablo console and recurring revenue indicates increasing market adoption.
• Significant improvement in gross margin reflects enhanced operational efficiency.
• Substantial reduction in cash used in operating activities demonstrates progress towards profitability.
• The company shipped its 3 millionth Tablo treatment during the quarter, adding 1 million treatments in approximately 12 months.
• Reaffirmation of 2025 revenue and gross margin guidance provides confidence in future performance.
• Special exemption received in January for products that serve the chronically disabled in addition to its exemption under the U.S.-Mexico-Canada Agreement (USMCA) means that proposed and recently enacted tariffs are expected to have no impact on the company.

Negatives

• Net loss was $25.8 million, or ($3.66) per share, compared to net loss of $39.9 million, or ($11.77) per share, for the same period in 2024.
• The company had approximately $210 million in cash, including restricted cash, cash equivalents and short-term investments following the closing of a financing announced on January 6, 2025, but total cash, including restricted cash, cash equivalents and short-term investments, was $192 million as of March 31, 2025.

Risks

• The company's forward-looking statements are subject to risks and uncertainties, as detailed in their SEC filings.
• Stranded manufacturing overhead costs impacted non-GAAP gross margin by approximately 230 basis points.
• The company continues to incur net losses, although the losses are decreasing year-over-year.

Future Outlook

Outset Medical reiterated its 2025 revenue guidance of $115 million to $125 million and expects non-GAAP gross margin in the high-30% range; the company continues to expect to use less than $50 million of cash in 2025.

Management Comments

• Outset's results in the first quarter reflect the strong progress we have made with our commercial transformation, the durable competitive differentiation of Tablo for acute and home hemodialysis, and the meaningful impact our operational execution is having on our path to profitability, said Leslie Trigg, Chair and Chief Executive Officer.
• Console placements grew, utilization-driven recurring revenue remained strong, and we demonstrated ongoing operating leverage during the quarter.
• Importantly, we continued to grow our installed base with providers and patients in the acute and home settings who are seeing firsthand the significant benefits Tablo can deliver.

Industry Context

Outset Medical's focus on reducing the cost and complexity of dialysis aligns with the broader industry trend of shifting towards more accessible and convenient healthcare solutions; the Tablo system's FDA clearance for use from the hospital to the home positions the company well in the expanding home dialysis market.

Comparison to Industry Standards

• The 20% growth in recurring revenue is a positive sign, indicating increasing utilization of the Tablo system, which is a key metric for medical device companies.
• Companies like Baxter and Fresenius Medical Care, which are major players in the dialysis market, also focus on recurring revenue streams through consumables and services.
• Outset's gross margin improvement to 37.2% is a step in the right direction, but still lags behind the industry leaders, which typically have gross margins in the 40-50% range.
• The reduction in cash burn is a critical factor for Outset, as it demonstrates progress towards financial sustainability; many smaller medical device companies struggle with high cash burn rates in their early stages.

Stakeholder Impact

• Shareholders will likely react positively to the revenue growth, margin improvement, and reduced cash burn.
• Employees may benefit from the company's progress towards profitability and financial stability.
• Customers (providers and patients) will benefit from the continued innovation and expansion of the Tablo system.
• Suppliers may see increased demand as Outset's business grows.
• Creditors may view the company as a lower credit risk due to its improved financial performance.

Next Steps

• Outset will host a conference call on May 7, 2025, to discuss the first quarter 2025 financial results.
• The company will continue to execute its commercial transformation and operational efficiency initiatives.
• Outset will focus on expanding its installed base of Tablo systems in acute and home settings.

Key Dates

Keywords

Outset Medical, Tablo Hemodialysis System, dialysis, revenue, gross margin, recurring revenue, financial results, medical technology